We performed a nationwide study to determine the distributions of the signs and clinical markers of systemic lupus erythematosus (SLE) and identify any patterns in their distributions to allow patient subclassification. We obtained 256,999 patient-year records describing the disease status of SLE patients from 2003 to 2010. Of these, 14,779 involved patients diagnosed within the last year, and 242,220 involved patients being followed up. Along with basic descriptive statistics, we analyzed the effects of sex, age and disease duration on the frequencies of signs in the first year and follow-up years. The patients and major signs were clustered using the Ward method. The female patients were younger at onset. Renal involvement and discoid eczema were more frequent in males, whereas arthritis, photosensitivity and cytopenia were less. Autoantibody production and malar rash were positively associated with young age, and serositis and arthritis were negatively associated. Photosensitivity was positively associated with a long disease duration, and autoantibody production, serositis and cytopenia were negatively associated. The SLE patients were clustered into subgroups, as were the major signs. We identified differences in SLE clinical features according to sex, age and disease duration. Subgroups of SLE patients and the major signs of SLE exist. Lupus (2014) 23, 1435-1442.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disorder that involves multiple organs and can lead to severe complications including cerebral infarction, myocardial infarction, infection, renal failure and a poor prognosis. [1] [2] [3] [4] SLE is characterized by the heterogeneity of its clinical features, and we have yet to fully understand this heterogeneity, which is one of the reasons why classification criteria for SLE 5 were developed, and new criteria were recently proposed. 6 Epidemiological studies of SLE Epidemiological studies of SLE can be classified into two types. The first type involves studies on relatively detailed issues, including the clinical features of SLE, that included only a limited number of patients. The second type involves studies on limited epidemiological indices, such as the incidence and prevalence of the condition, that included many registrants. Most of the first type of studies were hospital-, clinic-or limited regionbased studies with fewer than 1000 SLE patients, [7] [8] [9] [10] [11] although some of these studies recruited participants from multiple regions within a nation. 12 There have been only two national registry-based studies of SLE, which were performed in Taiwan and Japan. 13, 14 The sample sizes of these two studies were 22,182 and 21,405, respectively. SLE is three to 10 times more common in females than in males. 15 The age at onset of SLE peaks from 15 to 30, and the female:male ratio has been reported to be highest in individuals of reproductive age and decreases in adolescence and old age. 16 While some European studies have reported differences in the age at onset between males and females, 17 a relatively large study involving 1790 cases from China did not detect a significant difference in the mean onset age between the sexes. 18 Thus, it is unclear whether there is no difference in the onset age of SLE between males and females or whether such differences are observed only in patients of European descent.
Signs and clinical markers of SLE
SLE produces a wide range of clinical signs, including physical signs and laboratory findings. Various reports have detected associations between the clinical features of SLE and age/sex, either at disease onset or throughout the clinical course of the condition. Thus, these reports suggested that age and/ or sex can affect the signs of SLE. Efforts have been made to identify subgroups of SLE based on clinical manifestations. 19, 20 However, limited power of previous reports made it difficult to draw conclusions. A detailed analysis of the clinical features of SLE in a large-scale study would increase our understanding of the clinical heterogeneity of SLE.
Here, we performed a nationwide surveillance study of patients with SLE in Japan to characterize the epidemiological and clinical features of SLE. As far as we know, this is the largest such study to have ever been conducted.
Patients and methods

SLE patient registration
In Japan, a total of 56 diseases are defined as ''Nanbyo (intractable disease)'' and patients are given a questionnaire about their clinical status and history, which is filled out by the clinician providing their care, during registration. The clinicians are not limited to specialists for the diseases. The registered information is used for making decisions by experts on the public financial support provided for their medical care. Each patient is enrolled as a new registrant in the first year after diagnosis, and his or her registration is renewed annually by different forms from the first ones (follow-up registry). SLE is one of these ''Nanbyo.'' This registry-based financial support system is well known throughout the country, and Japanese public health departments and health care professionals believe that the vast majority of patients with the diseases that receive medical care are registered annually.
Clinical information in the questionnaire for the SLE forms is listed in Supplementary Table 1 .
We obtained text files electronically converted from nationwide registry data about SLE in Japan from 2003 to 2010. 14 Although the text files did not cover all the registrants, in total, 14,779 new registries were obtained from 2003 to 2010 and we adopted 2009 (44,249 patients), which covered the largest parts of the annual total registries (81.2%) as a year with representative follow-up data after we found that each year's follow-up registries displayed similar basic statistics. For new registries, we omitted suspected duplicate registries and identified 14,030 registrants as novel for the purposes of this study. We extracted 9374 registries for which information about disease onset was available and for which it could be confirmed that disease onset had occurred within the last year. Schematic images of quality control of the dataset were illustrated in Supplementary Figure 1 . We evaluated two patient groups; the first group, which was collected from 2003 to 2010, consisted of patients who had been diagnosed with SLE within the last year, and the other group consisted of all patients in the representative year, 2009. We called these two groups the ''novel SLE'' and ''all SLE'' groups, respectively.
Clinical information
We extracted information about the patients' clinical features including the 11 major signs included in the American College of Rheumatology (ACR) classification, 5 age, sex, age at diagnosis, and complications (infection, bone necrosis, compression fracture of bone, gastric ulcers, myocardial infarction and cerebral infarction) from the registry for all registrants. Some items, including information about antinuclear antibody (ANA) positivity, anti-Smith (anti-Sm) antibody positivity, anti-doublestranded DNA (anti-dsDNA) antibody positivity, the occurrence of biological false-positives on the syphilis test, lupus anti-coagulant positivity and anticardiolipin antibody positivity, were available only for the novel group (Supplementary Table 1 ).
Sex ratio
The female:male ratio was estimated in the all SLE group.
Age distribution of SLE patients
Age at onset was compared between males and females in the novel SLE and all SLE groups.
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The significance of the difference was tested by logistic regression analysis.
Analysis of SLE signs and clinical markers in patients with SLE
The frequencies of SLE signs and clinical markers were analyzed in the novel and all SLE groups. The effects of age, sex and disease duration were assessed separately and in combination by multiple logistic regression analysis. Clustering of the major signs and patients was performed in 6637 patients in the novel SLE group for whom data regarding the 11 major signs and clinical markers were available and 10,000 randomly selected patients in the all SLE group for whom data regarding the 10 major signs and clinical markers other than ANA were available (Supplementary Figure 1) . The associations between complications and the patients' basic information, SLE signs and clinical markers were also analyzed. We regarded autoantibody positivity at any point during the disease course as positivity.
Statistical analysis
Statistical analyses were performed using the R or SPSS (ver18) software.
Results
Female ratio of SLE
The female:male ratio was 8.14 in the all SLE group and was comparable to those described in previous reports (8.1-12.5). [21] [22] [23] A comparison of the age distributions of the male and female SLE patients in the all SLE group showed that the females were younger than the males (p ¼ 0.00031, Figure 1(a) ). The females were also younger at onset than the males (p ¼ 4.1 Â 10 À62 , Figure 1(b) ).
Prevalence of clinical features and the effects of age and sex on them in the all SLE group
The prevalence of the 10 major signs of SLE (as outlined by the ACR, except for ANA positivity) varied (Figure 2 (a), Supplementary Table 2 ). Cytopenia and arthritis were the two most common signs, and serositis was the least common sign. The frequencies of some of the 10 SLE signs differed markedly between males and females ( Figure 2(b) ). An analysis of the effects of age on the frequencies of these signs revealed four patterns: increases with age, decreases with age, a U-shaped age distribution (lowest in middle aged subjects), and an inverse-U shaped age distribution (highest in middle-aged subjects) ( Figure 2(c) ). An analysis of the effects of disease duration on the frequencies of these signs revealed that most of them were frequently observed in the short duration after onset. The signs' disease durationbased frequency patterns were similar to their age-based patterns. Photosensitivity was the only sign associated with a long disease duration ( Figure 2(d) ). Discoid eczema was the only sign that was not associated with disease duration. The detailed results are shown in Supplementary  Figure 2 and Supplementary Table 3 , and further analyses of the detailed signs of SLE are shown in the Supplementary notes and Supplementary Figure 3 . Prevalence of signs and clinical markers and the effects of age and sex on them in the novel SLE group
The prevalence of the major signs of SLE also varied in the novel SLE patients, and the order of the signs' frequencies (i.e. from highest to lowest) was different from that observed in the all SLE group (Figure 3(a) and Supplementary Table 2 ). Except for cytopenia, all of the SLE major signs were affected by sex in the same manner as was observed in the all SLE group according to multiple logistic regression analysis (Figures 2(b) and 3(b) and Supplementary  Figure 4(a) ). The associations between age and the SLE signs differed between the novel and all SLE groups for four of the 10 items (Figures 2(c) and 3(c) and Supplementary Figure 4 ). Two patterns of difference were observed. The first type involved a positive association with age being observed only in the novel SLE group. The other type involved a positive association with age not being observed in the novel SLE group. Oral ulcers exhibited the former pattern (p ¼ 3.9 Â 10 À6 ), and renal involvement, cytopenia and arthritis displayed the latter pattern (p > 0.019). Sex-specific age associations showed a third pattern: opposite associations in the novel and all SLE groups. Namely, cytopenia was associated with old age in the males belonging to the novel SLE group, while it was associated with young age in the males in the all SLE group. In addition, three signs showed specific associations with age in the novel SLE group. The frequency of serositis increased age-dependently, whereas the frequencies of renal involvement and arthritis showed U and inverse-U patterns, respectively. The detailed results of the analyses and further analyses are shown in the Supplementary notes and Supplementary Table 4 .
Clustering analysis of the coexistence of signs and clinical markers in the all SLE and novel SLE groups
Clustering analysis of the 11 signs in the patients in the novel SLE group revealed that they could be divided into two groups; namely, a group containing autoantibody positivity, ANA positivity, cytopenia and arthritis, and another group including the other seven signs and markers (Figure 4(a) ). The novel SLE patients (6637) were also subjected to clustering analysis, which showed that they could be classified into 10 clusters according to their signs (Figure 4(b) ). The sign frequencies and the numbers of SLE patients in each cluster are shown in Supplementary Table 5 . Cluster analysis of the 10 major SLE signs (not including ANA) in the all SLE group showed that they could be subgrouped into two clusters with the similar characteristics as those observed in the analysis of the novel SLE group although differences were observed among the finer cluster divisions (Figure 4(c) ). Cluster analysis of 10,000 randomly selected SLE patients from the all SLE group produced eight clear clusters (Figure 4(d) and Supplementary Table 6 ). The patterns of clusters partly matched those observed in the novel SLE group.
Further analyses: complications of SLE and the distributions of specific autoantibodies
The complications of SLE were also assessed in the all SLE group, as were the effects of age, sex and disease duration. The associations of autoantibodies with complications were assessed according to age, sex and disease duration to assess their utility as predictive markers. The associations between complications and each SLE patient cluster were also analyzed. See the Supplementary notes for details.
Discussion
Although some small studies did not report a significant difference in age at onset between the sexes, 18 our large-scale study demonstrated that female patients developed SLE at a younger age than male patients. We evaluated the clinical features of two patient populations, ''the novel As a result, we obtained evidence of associations between SLE signs and age, sex and disease duration. In our study, the frequencies of 11 major signs were similar to those obtained in previous reports from Asian and European countries both in the novel SLE and all SLE groups with the exception of serositis (25.3% in the novel SLE group, 4.6% in the all SLE group; 5%-22% at onset and 20%-40% prevalence in previous studies). 18, [23] [24] [25] [26] [27] This difference might have been due to the relative difficulty of detecting serositis compared with other features.
We validated previous reports of higher frequencies of serositis, 28,29 renal involvement 29, 30 and discoid eczema [29] [30] [31] in males and higher frequencies of photosensitivity 30 and oral ulcers 30 in females. Although neurological involvement was reported to be more common in males in two previous reports, 32, 33 our study did not find any difference between the sexes. The difference between the sexes in the frequency of malar rash is disputed, and our study did not detect any sex difference. Our results indicate that any inter-sex difference in neurological involvement and malar rash is very small. The sex difference in the frequency of arthritis is also disputed, and we observed a significantly higher frequency of arthritis in females (47.0% in females and 36.0% in males with p ¼ 1.3 Â 10 À44 ).
Only a few previous studies comprising more than 500 patients have examined the effects of age on the clinical manifestations of SLE. 18, 28, 34, 35 Previous studies reported positive associations of younger age with malar rash, discoid eczema, autoantibody production and photosensitivity, 18, 30 and we confirmed these associations. In addition, we demonstrated that serositis and neurological involvement were positively associated with older age. Renal involvement was associated with younger age only in the novel SLE group.
No studies have ever analyzed the detailed effects of disease duration on SLE signs. Most of the major signs and clinical markers of SLE, especially serositis, displayed higher prevalence in the patients with short disease durations. Only the prevalence of photosensitivity increased according to disease duration. Discoid eczema was not associated with disease duration. We performed similar analyses for more detailed signs of SLE (Supplementary notes).
The 11 SLE signs were classified into two groups according to their manifestation patterns in the novel SLE group: group 1 (ANA, autoantibody positivity (anti-Sm antibody and anti-dsDNA antibody), cytopenia, and arthritis) and group 2 (malar rash, discoid eczema, photosensitivity, oral ulcers, neurological involvement, serositis and renal involvement). The first group included hematoserological abnormalities such as cytopenia and arthritis was considered to be an inflammatory/ autoimmunity-related reaction and so was classified with the hematoserological abnormalities because of its reduced organ specificity compared to the items in group 2. Therefore, we called group 1 the hematoserological group and group 2 the organspecific group. In the all SLE group, such clear clustering was not very apparent, which might have been because individual patients tended to present with various features during their clinical courses.
The SLE patients in the novel SLE group were clustered into 10 groups according to the signs that they displayed. These groups were not associated with sex or age (analysis of variance (ANOVA), data not shown). At onset, the frequencies of the 10 groups ranged from 4.0% to 22.4%. The 10 groups were characterized as: represented by (1) neurological involvement (22.4%), (2) discoid eczema (10.6%), (3) a lack of autoantibodies other than ANA (12.7%), (4) oral ulcers (9.1%), (5) renal involvement (9.9%), (6) photosensitivity (5.7%), (7) a lack of arthritis (6.5%), (8) serositis (9.8%), (9) malar rash (4.0%) and (10) others (9.3%). It should be noted that each group was represented by one of the items in the organ-specific group or a lack of an item in the hematoserological group. These findings suggest that the items in the organ-specific group are the predominant determinants of a patient's condition. In the all SLE group, eight clusters, which displayed frequencies ranging from 3.9% to 31.5%, were determined. The clusters were characterized as follows: 1) no signs or markers (6.9%), 2) cytopenia alone (5.1%), 3) autoantibody positivity alone (3.9%), 4) cytopenia and autoantibody positivity only (5.9%), 5) arthritis (9.1%), 6) renal involvement (16.4%), 7) neurological signs and serositis (21.3%) and 8) others (31.5%). The novel SLE and all SLE groups shared two clusters with similar characteristics, i.e. the ''neurological signs'' and ''renal involvement'' clusters. The reduced frequencies of signs and clinical markers observed in the all SLE group led to clusters based on one or no signs.
The lack of information about ANA during the chronic phase might also have reduced the number of clusters. We performed five rounds of resampling, each of which involved 10,000 patients, and the same clusters were maintained (data not shown). These results confirm that SLE patients and signs can be subgrouped into clear clusters. However, the 11 or 10 signs of SLE could not consistently explain the division of clusters among different stages of the disease. This raised the possibility that underlying factors related to the pathology of SLE other than the 11 signs exist. While we analyzed the associations between clusters and clinical signs or complications, we could not analyze the association between clusters and death because of a lack of information. Although the follow-up questionnaire included information about death causes (data not shown), this information was not filled out in most cases. This could be explained by the system of the nationwide study in which patients ask physicians to fill out the questionnaire. Associations between clusters in all SLE group and some complications (Supplementary notes) suggest the possibility that clusters are associated with severity and prognosis of SLE. Further follow-up studies would clarify the clinical characteristics of the abovementioned clusters.
Finally, we would like to comment on our data source. As the primary purpose of the national registry is to determine whether patients qualify for public financial aid, there could be a bias toward the over-rating of the signs. Despite our concern about such overestimation, the frequencies of individual signs in our study were similar to those described in previous reports from Asian countries, 36 indicating that any over-rating was not too problematic. Considering the number of subjects analyzed in the current study and the fact that the same tendencies were observed during each year (data not shown), our results regarding the patterns of signs and the associations between these signs and gender, age and disease duration in Japanese SLE patients should be regarded as conclusive.
In conclusion, we have obtained conclusive evidence about the distributions of the clinical features of SLE and their relationships with sex, age and age at onset.
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